扩散加权MRI与18F-FDG PET/CT评估局部晚期食管鳞癌新辅助放化疗反应
该回顾性研究纳入54例局部晚期食管鳞癌患者,在新辅助放化疗前后及放疗10-15次时行DW-MRI和18F-FDG PET/CT检查,比较病理完全缓解与非完全缓解患者的影像参数差异。结果显示∆MTV和∆TLG在pCR与非pCR间有显著差异,ADCduring联合TLG-Tpost预测原发灶pCR的AUC最高达0.914。
要点
- ∆MTV和∆TLG可区分pCR与非pCR患者。
- ADCduring联合TLG-Tpost预测pCR-T的AUC为0.914。
- 18F-FDG PET/CT有助于nCRT后再分期及手术决策。
核心结论
- 18F-FDG PET/CT有助于nCRT后再分期和手术决策,整合PET/CT与DW-MRI参数能更准确识别食管鳞癌原发灶的病理反应。
研究设计与样本
- 回顾性分析2017年8月至2019年9月54例接受nCRT的局部晚期食管鳞癌患者。
- DW-MRI于nCRT前、放疗10-15次时及nCRT完成后4-6周进行,18F-FDG PET/CT于nCRT前及完成后4-6周进行。
主要发现
- ∆MTV和∆TLG在pCR与非pCR患者间有显著差异。
- nCRT后SUVmax-Tpost、MTV-Tpost、TLG-Tpost及∆SUVmax-T、∆MTV-T在pCR-T与非pCR-T间有显著差异。
- 食管肿瘤ADC在nCRT后升高,ADCduring、ADCpost及∆ADCduring在pCR-T与非pCR-T间有显著差异。
- ROC分析显示ADCduring联合TLG-Tpost模型预测pCR-T的AUC最高(0.914),敏感度90.0%、特异度86.4%。
临床怎么用
- 可利用18F-FDG PET/CT进行nCRT后再分期并辅助手术决策。
- 可整合DW-MRI的ADCduring与PET/CT的TLG-Tpost参数以提高原发灶病理反应预测准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is a currently widely used strategy for locally advanced esophageal cancer (EC). However, the conventional imaging methods have certain deficiencies in the evaluation and prediction of the efficacy of nCRT. This study aimed to explore the value of functional imaging in predicting the response to neoadjuvant chemoradiotherapy (nCRT) in locally advanced esophageal squamous cell carcinoma (ESCC). METHODS: Fifty-four patients diagnosed with locally advanced ESCC from August 2017 to September 2019 and treated with nCRT were retrospectively analyzed. DW-MRI scanning was performed before nCRT, at 10-15 fractions of radiotherapy, and 4-6 weeks after the completion of nCRT. 18F-FDG PET/CT scans were performed before nCRT and 4-6 weeks after the completion of nCRT. These 18F-FDG PET/CT and DW-MRI parameters and relative changes were compared between patients with pathological complete response (pCR) and non-pCR. RESULTS: A total of 8 of 54 patients (14.8%) were evaluated as disease progression in the preoperative assessment. The remaining forty-six patients underwent operations, and the pathological assessments of the surgical resection specimens demonstrated pathological complete response (pCR) in 10 patients (21.7%) and complete response of primary tumor (pCR-T) in 16 patients (34.8%). The change of metabolic tumor volume (∆MTV) and change of total lesion glycolysis (∆TLG) were significantly different between patients with pCR and non-pCR. The SUVmax-Tpost, MTV-Tpost, and TLG-Tpost of esophageal tumors in 18F-FDG PET/CT scans after neoadjuvant chemoradiotherapy and the ∆ SUVmax-T and ∆MTV-T were significantly different between pCR-T versus non-pCR-T patients. The esophageal tumor apparent diffusion coefficient (ADC) increased after nCRT; the ADCduring, ADCpost and ∆ADCduring were significantly different between pCR-T and non-pCR-T groups. ROC analyses showed that the model that combined ADCduring with TLG-Tpost had the highest AUC (0.914) for pCR-T prediction, with 90.0% and 86.4% sensitivity and specificity, respectively. CONCLUSION: 18F-FDG PET/CT is useful for re-staging after nCRT and for surgical decision. Integrating parameters of 18F-FDG PET/CT and DW-MRI can identify pathological response of primary tumor to nCRT more accurately in ESCC.
引用
- Xu X, Sun ZY, Wu HW, et al. Diffusion-weighted MRI and 18F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Radiat Oncol. 2021. PMID: 34281566. doi:10.1186/s13014-021-01852-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。